DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > Graduate School of Biomedical Sciences > Articles in academic journal >

Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals


File Description SizeFormat
HepRes48_E232.pdf227.28 kBAdobe PDFView/Open

Title: Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals
Authors: Ichikawa, Tatsuki / Miyaaki, Hisamitsu / Miuma, Satoshi / Taura, Naota / Motoyoshi, Yasuhide / Akahoshi, Hiroshi / Nakamura, Satomi / Nakamura, Junpei / Takahashi, Youichi / Honda, Tetsurou / Yajima, Hiroyuki / Uehara, Ryouhei / Hino, Naoyuki / Narita, Syouhei / Tanaka, Hisaya / Sasaki, Seina / Nakao, Kazuhiko
Issue Date: Feb-2018
Publisher: 日本肝臓学会 / The Japan Society of Hepatology
Citation: Hepatology Research, 48(3), pp.E232-E239; 2018
Abstract: Aim: Direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection have a significantly high sustained virologic response rate after a short treatment course and do not have any severe adverse effects. Patient-reported outcomes (PROs) have become increasingly important to assess the total impact of a chronic disease. We aimed to evaluate the changes in symptoms of patients with HCV infection treated with DAAs by using PROs. Methods: A total of 107 patients with chronic HCV infection were treated with DAAs. Daclatasvir/asunaprevir or sofosbuvir/ledipasvir was used for HCV 1B infection, and sofosbuvir/ribavirin for HCV 2A/2B infection. The PROs measured at the start of treatment and 1 year after the start of treatment were cirrhosis-related symptom score (CSS), presence of restless legs syndrome (RLS), Epworth sleepiness scale (ESS), Pittsburg sleep quality index (PSQI), Kessler 6 score (K-6), and the SF-36 to measure quality of life (QOL). All patients had a sustained virologic response rate of 24. Results: The CSS, PSQI, K-6, and RLS scores were improved 1 year after beginning treatment. However, QOL had not recovered. Changes in total CSS were correlated with HCV genotype, sex, hypertensive drug use, serum low-density lipoprotein, and ESS at the start of treatment and RLS 1 year after the start of treatment. The factors that contributed to worsening of CSS were HCV genotype 2B and RLS 1 year after the start of treatment. Conclusion: Treatment with DAAs eliminated HCV-RNA and improved most symptoms, but QOL did not recover.
Keywords: direct-acting antivirals / hepatitis C virus / patient-reported outcomes / quality of life, symptoms
URI: http://hdl.handle.net/10069/38333
ISSN: 13866346
DOI: 10.1111/hepr.12974
Rights: © 2017 The Japan Society of Hepatology. This is the peer reviewed version of the following article: Hepatology Research, 48(3), pp.E232-E239; 2018, which has been published in final form at http://dx.doi.org/10.1111/hepr.12974. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Type: Journal Article
Text Version: author
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/38333

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace